Victory For Takeda Abbott In Prostate Drug Patent Suit

Law360 (December 14, 2005, 12:00 AM EST) -- A jury has upheld a patent for a prostate cancer treatment held by Takeda Abbott Pharmaceuticals, marking a victory for the company in its litigation against pharmaceutical companies QLT Inc. and Sanofi-Synthelabo.

QLT said it plans to appeal the jury verdict.

TAP, a joint venture between Takeda Chemical Industries and Abbot Laboratories, filed the suit in 2003, alleging that the Eligard prostate cancer treatment controlled by all three defendants infringes a TAP patent.

Eligard was developed by Atrix Laboratories, which was purchased by QLT in November...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.